ANGIOCHEM COMPLETES A $6 MILLION FINANCING TO ADVANCE CNS DRUG DEVELOPMENT

AngioChem Inc., a biotechnology company focused on developing innovative drugs for the treatment of brain diseases, announced today that it has completed a private financing, raising a total of $6 million. The financing was led by BDC Venture Capital and Boston-based VIMAC Milestone Medica Fund (VMM). "BDC was instrumental in guiding management towards the key proof of concept experiments over the past year as well as working with us to facilitate this round. We are eager to work with them and management to drive AngioChem's innovative therapies into the clinic" said Dr. Sena Biswas, Managing Director of VMM.

CCNMatthews (http://www.ccnmatthews.com/news/releasesfr/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=571592)